Mesothelioma

Surgery Improves Quality of Life for Patients With Malignant Pleural Mesothelioma

Surgery Improves Quality of Life for Patients With Malignant Pleural Mesothelioma

By

Undergoing pleurectomy and decortication for malignant pleural mesothelioma generally leads to improved quality of life after the surgery.

Modern Management of Malignant Pleural Mesothelioma

Modern Management of Malignant Pleural Mesothelioma

[Lung Cancer: Targets and Therapy] This research evaluates the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM).

Combination of Live Bacterium and Chemotherapy Improves Response Rate in Patient With Pleural Mesothelioma

Combination of Live Bacterium and Chemotherapy Improves Response Rate in Patient With Pleural Mesothelioma

By

Patients with malignant pleural mesothelioma (MPM) experienced greater than 90% disease control and 59% response rate after immunotherapy with live bacterium combined with chemotherapy.

Research Shows Drug Inhibits Mesothelioma Growth

Research Shows Drug Inhibits Mesothelioma Growth

By

A new drug might help successfully treat mesothelioma, one of the deadliest cancers, according to results from cell culture and mouse xenograft models of the disease.

Tumor Weight and Volume May Improve Mesothelioma Staging Accuracy

By

Improvements in scoring the severity of mesothelioma could be achieved by considering both tumor weight and volume.

Immunotherapy drug pembrolizumab shows promise for patients with mesothelioma

By

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in approximately 76% of patients with pleural mesothelioma.

Investigational personalized cellular therapy tolerated well by patients

Investigational personalized cellular therapy tolerated well by patients

By

An early stage trial for mesothelioma and pancreatic and ovarian cancers has explored utilizing a patient's own immune cells, genetically modified to target tumors.

High-dose radiotherapy doesn't offer survival benefit in mesothelioma

By

Treatnent with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to phase II trial data.

PD-L1 a possible immunotherapy target in mesothelioma

By

Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.

Mesothelioma distinguished from noncancerous tissue by biomarkers

Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma and noncancerous pleural tissue with reactive mesothelial proliferations.

Novel cancer vaccine promising against ovarian cancer and mesothelioma

By

A protein engineered to combine a molecule targeting a tumor-cell-surface antigen with another protein that stimulates immune functions was found to prolong survival in animal models for ovarian cancer and mesothelioma.

Radiation before surgery more than doubles mesothelioma survival

Treating mesothelioma with radiation before surgery resulted in a 3-year survival rate that was more than double compared with that of treating with surgery first, according to new research.

Rib cage lymph nodes are prognostic for mesothelioma

By

For the first time, researchers have shown the predictive power of a group of overlooked lymph nodes that could serve as a better tool to stage and ultimately treat patients with malignant pleural mesothelioma.

A roundup of FDA news from July 2013

By

The FDA has granted orphan drug designation to a cancer stem cell inhibitor known as VS-6063, or defactinib, for use in the treatment of mesothelioma, a rare form of lung cancer.

Diagnosis delayed for certain cancers and certain patients

A large UK study found a wide variation between cancer types in patients who had visited their general practitioner 3 or more times before cancer diagnosis.

Lung-sparing surgery/phototherapy combo improves survival in mesothelioma

Lung-sparing surgery combined with photodynamic therapy (PDT) improved overall survival in patients with pleural mesothelioma compared with those treated with conventional therapy and PDT.

Kidney cancer drug may provide much-needed treatment for mesothelioma

Temsirolimus, a kinase inhibitor commonly used to treat advanced renal cell carcinoma, may increase the effectiveness of chemotherapy administered in the treatment of mesothelioma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs